No Data
No Data
10 Health Care Stocks Whale Activity In Today's Session
Wedbush Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Raises Target Price to $45
Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2025 MDA Clinical and Scientific Conference
Piper Sandler Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $51
Scotiabank Initiates Coverage On Edgewise Therapeutics With Sector Outperform Rating, Announces Price Target of $50
Truist Financial Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating